Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jul 15 04:00PM ET
Dollar change
Percentage change
IndexRUT P/E- EPS (ttm)- Insider Own54.86% Shs Outstand43.12M Perf Week29.54%
Market Cap427.32M Forward P/E- EPS next Y-3.82 Insider Trans9.55% Shs Float19.46M Perf Month-27.87%
Income- PEG- EPS next Q-0.70 Inst Own38.56% Short Float14.77% Perf Quarter-56.50%
Sales- P/S- EPS this Y96.30% Inst Trans- Short Ratio4.62 Perf Half Y-
Book/sh8.37 P/B1.18 EPS next Y-15.06% ROA- Short Interest2.87M Perf Year-
Cash/sh8.58 P/C1.16 EPS next 5Y- ROE- 52W Range6.75 - 35.06 Perf YTD-66.97%
Dividend Est.- P/FCF- EPS past 5Y- ROI- 52W High-71.73% Beta-
Dividend TTM- Quick Ratio17.17 Sales past 5Y-37.90% Gross Margin- 52W Low46.81% ATR (14)1.17
Dividend Ex-Date- Current Ratio17.17 EPS Y/Y TTM- Oper. Margin- RSI (14)51.46 Volatility11.99% 15.70%
Employees96 Debt/Eq0.03 Sales Y/Y TTM- Profit Margin- Recom1.40 Target Price35.80
Option/ShortYes / Yes LT Debt/Eq0.02 EPS Q/Q- Payout- Rel Volume0.54 Prev Close9.79
Sales Surprise- EPS Surprise-33.33% Sales Q/Q- EarningsMay 14 AMC Avg Volume622.02K Price9.91
SMA2018.61% SMA50-15.27% SMA200-47.33% Trades Volume335,476 Change1.23%
Date Action Analyst Rating Change Price Target Change
Jul-03-24Initiated H.C. Wainwright Neutral $8
Mar-04-24Initiated Wells Fargo Overweight $44
Mar-04-24Initiated Morgan Stanley Overweight $40
Mar-04-24Initiated Leerink Partners Outperform $48
Mar-04-24Initiated JP Morgan Overweight $39
Today 04:05PM
Jun-20-24 08:55AM
Jun-17-24 04:05PM
Jun-10-24 04:05PM
Jun-07-24 08:55AM
10:54PM Loading…
May-14-24 10:54PM
Apr-11-24 05:01PM
Mar-29-24 02:59PM
Mar-26-24 04:05PM
Mar-14-24 07:00AM
Mar-07-24 07:26PM
Feb-12-24 04:39PM
Feb-07-24 10:29PM
Kyverna Therapeutics, Inc. is a cell therapy clinical-stage biotechnology company. It develops treatments and potential cures for serious autoimmune diseases. The company was founded in June 2018 and is headquartered in Emeryville, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Walker Karen MarieChief Technology OfficerJun 06 '24Option Exercise4.429,63642,5919,636Jun 10 06:56 PM
Jones Ryan AlexanderChief Financial OfficerMay 28 '24Option Exercise0.7318,01613,15243,950May 29 04:33 PM
GILEAD SCIENCES, INC.10% OwnerFeb 12 '24Buy22.00910,00020,020,0004,126,119Feb 13 05:48 PM
Northpond Ventures III GP, LLCFormer 10% OwnerFeb 12 '24Buy22.00450,0009,900,000450,000Feb 12 05:51 PM
Bain Capital Life Sciences Inv10% OwnerFeb 12 '24Buy22.00450,0009,900,0003,163,868Feb 14 05:26 PM
Vida Ventures, LLC10% OwnerFeb 12 '24Buy22.00253,1365,568,992252,553Feb 14 07:04 PM